Novo Nordisk's AI and Pricing Gambits Battle a 23% Share Price Slump

Novo Nordisk shares staged a surprising 7.5% rally last week, a move that starkly contrasts with the company's sobering full-year forecast. The Danish pharmaceutical giant expects adjusted revenue and operating profit to decline by 5% to 13% in 2026, pressured by US pricing policies and patent expirations. Yet, investor focus has shifted to a bold strategic partnership with OpenAI, announced on April 14, aiming to embed artificial intelligence across the entire value chain by the end of 2026.

Concurrently, the company is launching an aggressive pricing offensive in the crucial US obesity drug market. Its new highest-dose formulation, Wegovy HD, is now available nationwide with a list price of $399 per month for cash-paying patients. This undercuts the key rival, Eli Lilly, by approximately 40%. Clinical data supports the move, showing patients on the new dose lost an average of 20.7% of their body weight, outperforming the 17.5% loss associated with the previous maximum dose.

Operational adjustments are unfolding alongside these strategic plays. After cutting nearly 7,800 positions last year, Novo Nordisk is now hiring again, adding around 2,000 new employees focused on production and research to bolster its core therapies. The OpenAI collaboration is designed to accelerate this focus, with AI models tasked with analyzing complex datasets to speed up drug discovery and development.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Further operational support came from European regulators, who approved a 48-hour temperature-controlled shipping window for Wegovy injections. This logistical change simplifies the "last mile" of distribution and is expected to meaningfully reduce delivery costs for the GLP-1 drug.

Despite these concerted efforts, the equity story remains challenging. The stock closed Friday at €34.47, leaving it down almost 23% since the start of the year and more than 50% below its 52-week high of €70.13. A Relative Strength Index (RSI) reading of 25 indicates the shares are deeply oversold, which may have contributed to the recent bounce. The company's ongoing multi-billion euro share buyback program has so far provided little sustained support against the dominant downtrend.

All eyes are now on the first-quarter 2026 results, due on May 6. This report will offer the clearest picture yet of how severely new US pricing agreements are impacting margins. It may also provide early indications of whether the operational shifts and the OpenAI partnership are yielding tangible benefits. Looking further ahead, a potential catalyst looms: management anticipates that the US Medicare program could begin covering its obesity medications by mid-2026, which would open access to millions of new patients. Until then, the company's strategic bets on AI and pricing are its primary weapons against a skeptical market.

Ad

Novo Nordisk Stock: New Analysis - 18 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69189586 |